News Press Releases

Halozyme Therapeutics To Present At The UBS 2015 Global Health Care Conference

HALO | May 12, 2015

SAN DIEGO, May 12, 2015 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will present at the UBS 2015 Global Health Care Conference in New York, on Monday, May 18^th, 2015 at 2:00 p.m. ET/11:00 a.m. PT. Dr. Helen Torley, president and chief executive officer, will provide a corporate overview.

The presentation will be webcast through the "Investors" section of Halozyme's corporate website at halozyme.com, and a recording will be made available for 90 days following the event. To access the live webcast, please log on to Halozyme's website approximately 15 minutes prior to the presentation to register and download any necessary audio software.

About Halozyme
Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies that target the tumor microenvironment. Halozyme's lead proprietary program, our investigational drug PEGPH20, applies a unique approach to targeting solid tumors, allowing increased access of co-administered cancer drug therapies to the tumor. PEGPH20 is currently in development for metastatic pancreatic cancer and non-small cell lung cancer and has potential across additional cancers in combination with different types of cancer therapies. In addition to its proprietary product portfolio, Halozyme has established value-driving partnerships with leading pharmaceutical companies including Roche, Pfizer, Janssen and Baxter for its drug delivery platform, ENHANZE™, which enables biologics and small molecule compounds that are currently administered intravenously to be delivered subcutaneously. Halozyme is headquartered in San Diego. For more information visit halozyme.com.

Contacts:
Schond Greenway
Halozyme Therapeutics
858-704-8352
ir@halozyme.com

Jim Mazzola
Halozyme Therapeutics
858-704-8122
ir@halozyme.com